EichorEICHOR
Condition: Ann Arbor Stage Iii Hodgkin Lymphoma Synced from ClinicalTrials.gov · August 03, 2026

Recruiting studies: Ann Arbor Stage Iii Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Ho
Phase 2 · 6 location(s) · University of Washington · NCT06745076Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06471738Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 · 1 location(s) · University of Washington · NCT06442475A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
EARLY_Phase 1 · 8 location(s) · AIDS Malignancy Consortium · NCT04139304
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.